What Purevax RCPCh Treats: Main Uses and Benefits

This vaccine is commonly used to provide support against four diseases in cats, including Feline Viral Rhinotracheitis, Feline Calicivirus, Chlamydophila felis, and Feline Panleukopenia. The product is designed to assist with managing these diseases, which may help reduce the overall symptom load.

It supports the management of symptom clusters related to upper respiratory and ocular discomfort, such as persistent sneezing and eye inflammation, as well as symptoms related to systemic imbalance like profound vomiting. This protection contributes to improved comfort during periods of heightened symptoms.

The product assists with maintaining functional stability when symptoms are more noticeable, and supports the animal during difficult episodes.

Quick Fact: Support for Symptom Clusters Related to Physiological Strain

The support provided by the product is relevant for easing symptoms associated with acute or episodic changes that create noticeable physiological strain. It is relevant for managing symptoms that interfere with daily comfort.

Regulatory References

1. UK Veterinary Medicines Directorate product information

The eligibility profile for the veterinary vaccine Purevax RCPCh is strictly defined by regulatory authorities based on three main criteria: the cat's age, its reproductive status, and its current health condition. These rules determine who is officially permitted to receive the vaccine and who is explicitly excluded.

Eligibility Scope

Official regulatory guidance permits use in healthy animals only. The product is established for active immunisation in cats aged 8 weeks and older. Kittens under this minimum age threshold are outside the population for which the product's use is formally established.

Absolute and Conditional Restrictions

Regulatory documents establish absolute non-eligibility for pregnant animals, stating the product is contraindicated and must not be used during gestation. Use in lactating animals is formally restricted, classified as not recommended.

Furthermore, any cat with a known hypersensitivity to the components is also excluded. The label also specifies that the primary vaccination course should be delayed in kittens where high levels of maternal antibodies are expected, such as those aged 9 to 12 weeks. There are no specific restrictions documented in the official labeling regarding use in cats with specific organ impairments like hepatic or renal conditions.

Interactions with other medicines and products

The officially documented interaction profile for Purevax RCPCh focuses primarily on physical incompatibility and co-administration rules with other veterinary vaccines. This product does not have documented interactions based on metabolic pathways, such as CYP enzymes or drug transporters, in its regulatory labeling.

Interaction Scope

Specific Co-administration Rules

Official Interaction Statements

The regulatory profile outlines mandatory procedural restrictions on preparation and use. Safety and efficacy data support the co-administration of the non-adjuvanted feline leukaemia vaccine through physical mixing, while the adjuvanted rabies vaccine requires administration on the same day but in separate injections. The mandatory constraint is the non-mixing requirement with all other unauthorized products to maintain stability and efficacy.

Purevax RCPCh, comprised of attenuated viral antigens, is introduced to the host immune system. These specific antigenic components, derived from Feline Parvovirus, Calicivirus, and Herpesvirus, are processed by antigen-presenting cells (APCs) and recognized by T and B lymphocytes. This specific recognition event triggers an intracellular signaling cascade culminating in the activation and subsequent clonal expansion of antigen-specific lymphocytes. The primary consequence of this cascade is the differentiation of B-cells into plasma cells that produce circulating antibodies, alongside the establishment of a population of memory T and B cells. This immunological programming creates a state of preparedness in the host. Upon subsequent exposure to the corresponding antigens, the memory cell population facilitates rapid B-cell differentiation and robust Cytotoxic T-lymphocyte (CTL) activation, accelerating the host's physiological response kinetics.

The administration of Purevax RCPCh follows a defined procedural protocol. The vaccine is exclusively administered via subcutaneous injection (SC route). This method is standardized across the primary and revaccination regimens.

Before use, the product—which is supplied as a lyophilisate and solvent—must be gently reconstituted immediately with the supplied solvent to form a uniform suspension. Only healthy animals should receive the product, and it should not be mixed with any other substance except for the supplied solvent or specific approved non-adjuvanted vaccines.

Dosing and Schedule

Administration follows a two-part schedule: the primary course and the long-term revaccination program, with a fixed volume of one dose (1 ml or 0.5 ml) per injection.

The primary course establishes the initial immune response. The subsequent revaccination schedule is structured to maintain long-term protection, utilizing a split-cycle approach where boosters for specific components are required at different time intervals.

Research Evidence / Overview of Studies for Purevax RCPCh

This overview summarizes the official research conducted on Purevax RCPCh, focusing on the types of studies performed and the evidence patterns that have been observed so far, as documented in regulatory findings. The information here does not constitute medical advice or treatment recommendations.

Evidence for Use in Feline Rhinotracheitis and Calicivirosis

Research for the two viral components was evaluated in controlled challenge studies and field immunogenicity trials. Controlled challenge studies were used in laboratory settings to examine how the vaccine was evaluated to measure changes in clinical signs (such as ocular and respiratory symptoms) following intentional experimental challenge. For Calicivirosis, research also examined outcomes related to measure viral excretion levels.

Studies monitored antibody levels (serological response) within one week following the primary vaccination course. The follow-up durations used to establish the immune measurement after the initial primary vaccination course (without a subsequent booster) were limited to one year.

Evidence for Use in Feline Panleucopenia

The evidence for the Feline Panleucopenia component was primarily evaluated using controlled challenge studies and immunogenicity trials. The study outcomes examined included the measurement of mortality rates and the measurement of clinical signs following experimental challenge. Research provides insight into the short-term changes measured within one week after the completion of the primary course.

As with the other components, the evidence for the duration of immunity after the initial primary course alone is limited to one year. Long-term effects are not fully established beyond the three-year documented follow-up period.

Research Gaps and What Remains Uncertain

One key research limitation is that the follow-up durations were limited, resulting in a shorter documented duration of immunity for the Chlamydiosis component (one year) compared to the viral components (three years) after re-vaccination. Additionally, for the Calicivirosis component, there is uncertainty regarding the consistent long-term outcome related to viral excretion, as one long-term study indicated the data were not reported at the full three-year follow-up. Data for certain subgroups, such as cats with existing comorbidities, remain insufficient.

Key Studies & References

1. SUMMARY OF PRODUCT CHARACTERISTICS: Purevax RCPCh lyophilisate and solvent for suspension for injection (UK VMD Regulatory File)

Common questions about Purevax RCPCh (FAQ)

Q: What is the official name and ATCvet code of the active ingredient?

The active components of Purevax RCPCh are antigens derived from four different pathogens: Feline Rhinotracheitis Herpesvirus, Feline Calicivirus, Chlamydophila felis, and Feline Panleucopenia Virus. According to official product classification, the drug is grouped under the ATCvet code QI06AJ05, which is the category for live and inactivated viral and bacterial vaccines for domestic cats.

Q: What is the full revaccination schedule, including all components?

The official product schedule indicates the first revaccination for all components is due one year after the primary course. Following this, the booster for the Chlamydiosis component is required annually. However, the boosters for the Feline Panleucopenia, Rhinotracheitis, and Calicivirosis components are required at intervals of up to three years, according to regulatory documents.

Q: Can the vaccine be used in a lactating animal?

Official product information states that the vaccine is not recommended for use in lactating animals (those that are currently nursing). This restriction is explicitly outlined in the regulatory label.

Q: What are the most common side effects (adverse reactions)?

Adverse reactions classified by regulators as Common (affecting 1 to 10 animals per 100) are typically temporary. These reported reactions may include transient apathy, a loss of appetite (anorexia), a temporary elevation in body temperature (hyperthermia), and minor local injection site reactions such as limited swelling, slight pain upon touch, or itching.

Q: Does this vaccine contain an adjuvant?

Official documentation indicates that this product is a non-adjuvanted vaccine. This means it is formulated to generate an immune response based on the quality of its antigens alone, without the need for chemical agents known as adjuvants.

Q: What is the shelf life of the solvent component alone before mixing?

The regulatory shelf life of the product as a whole (lyophilisate and solvent) is 18 months when stored correctly. The official label does not provide a separate, defined shelf life for the solvent component if it were stored or handled independently from the lyophilisate.

Storage and Disposal Requirements

The storage of Purevax RCPCh must strictly adhere to the conditions mandated in official regulatory documents to maintain stability and ensure safety.

These official statements define the mandatory environmental and handling constraints for the vaccine components, from initial storage to final disposal.